PeterMD provider review: what an independent read of the site shows

The company operates at getpetermd.com and organises its catalogue under six headings: increase testosterone, lose weight, improve sexual function, enhance performance, hair loss, and live longer. Everything ships direct to the patient. Nothing runs through insurance.

The homepage describes the company as "The Largest Online Healthcare Clinic in North America" and claims "Over 400,000 patients served" at "4.9/5, Based on 20k+ Reviews". Neither figure is sourced anywhere on the site, and the patient count is contradicted by the company's own tirzepatide page, which we come to below.

Here is the part that took us longest to find: nowhere on the site does PeterMD name a legal entity. No LLC, no Inc, no PA. The terms of service name the counterparty as simply "PeterMD", give a Vero Beach mailing address, run the contract under Oklahoma law, and name Tulsa, Oklahoma as one of the arbitration venues. The two pharmacies named in the same document have street addresses in Florida and Nevada.

The pitch is concierge-style access built on a subscription: a physician visit, ongoing monitoring, and medication delivery bundled into a monthly fee, with the consultation folded in rather than billed separately. In the longevity-telehealth category that structure is common. Maximus, AgelessRx and Henry Meds all run variants of it.

What is less common: PeterMD's site doesn't name the physician who signs your prescription, nor a medical director whose name a state board could look up. In a category built on the premise that a licensed doctor is behind every script, that absence is the story.

Testosterone replacement is the anchor product. The TRT page publishes three tiers: $79 per month on a 12-month plan, $109 per month on a six-month plan, and $139 per month billed monthly. Those are clearly presented and easy to compare, which is more than several competitors manage.

The longevity shelf is thinner than the category's marketing usually implies. The peptides category lists exactly three things: sermorelin injections in one-, two- and three-month supplies, NAD+ in capsule and injection form, and modafinil. Modafinil is a wakefulness-promoting agent, not a peptide; it is filed under "Peptides" anyway. There is no BPC-157, no CJC-1295/Ipamorelin and no GHK-Cu on the site.

State availability is published per product rather than site-wide, which is genuinely useful. Sermorelin is "NOT AVAILABLE TO THE FOLLOWING STATES: AL, AR, CA, ID, MI, NC". NAD+ excludes AL, AR, CA, ID, KY, LA, MT and SC. Tirzepatide is the exception, and § 10 explains why.

On its tirzepatide product page, PeterMD states: "On average, people on Tirzepatide lose 26% of their weight in a year*." The asterisk is the interesting part, and it does the opposite of a footnote's job. In full:

> \* Based on the average weight loss in three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

2.4 mg a week is the maintenance dose of semaglutide. Tirzepatide is dosed at 5, 10 and 15 mg. The evidence cited under a claim about tirzepatide is drawn from trials of a different molecule at a dose tirzepatide is never given at — and 68 weeks of semaglutide at 2.4 mg is the STEP programme, which reported mean weight loss around 15%, not 26%.

Read charitably, someone adapted a semaglutide marketing footnote and changed the drug name in the headline above it. Read plainly, the number on the page is not supported by the trials the page cites for it, and a reader who follows the asterisk to check is handed a citation for a product they are not buying.

The same page carries "Join 1,500,000+ PeterMD weight loss patients" and "Lose up to 1.5% of your body fat per week", neither sourced. The first is worth holding next to the homepage's "Over 400,000 patients served". One page claims nearly four times as many weight-loss patients as the other claims patients of any kind.

Sermorelin is the most defensible thing on the longevity shelf. It was approved as Geref in 1997 for pediatric growth hormone deficiency, withdrawn for business reasons rather than safety ones by 2009, and is now prepared by 503A compounding pharmacies against a prescription. PeterMD's sermorelin page is candid about the mechanics: one vial, "1 vial will last 4-6 weeks depending on the dose", mixing supplies and syringes included, and a one-time $70 provider appointment charge unless you are buying TRT.

Compounded semaglutide and tirzepatide sit in a different bucket, and one that has narrowed sharply. The FDA removed tirzepatide from the shortage list in December 2024 and semaglutide in February 2025. The wind-down ran on two clocks: February 18 and March 19, 2025 for tirzepatide, April 22 and May 22, 2025 for semaglutide. The mass-compounding pathway that let telehealth brands ship these drugs at scale no longer has a legal basis.

What remains is a narrow patient-specific exception under 503A, which requires clinical documentation that the brand-name drug is unsuitable for the specific patient. Whether PeterMD's current prescribing meets that standard is not something an outside reader can determine. What is visible is that the product pages don't explain the exception under which the drugs are being compounded.

There is very little here to describe. PeterMD's website doesn't name its prescribing physicians. It doesn't name a medical director. It doesn't publish state license numbers, board certifications, or a team page.

Two pharmacies are named in § 23 of the terms: "Absolute Pharmacy – 16011 N Nebraska Ave #103, Lutz, FL 33549" and "Partell Pharmacy – 5835 S. East Ave, Las Vegas, NV". That is more supply-chain transparency than most DTC telehealth brands offer. It is also, oddly, more than PeterMD offers about the clinicians writing the prescriptions.

Section 24 of the same document says "Prescriptions are sent electronically to a pharmacy of the patient's choosing" — which is hard to square with a named pair of compounding pharmacies and a subscription that includes shipping.

The product pages are clear on one point, at least: a provider appointment gates the prescription. The tirzepatide page states "DOCTOR APPOINTMENT REQUIRED before medication is shipped", and the sermorelin page adds that "Patients will be scheduled with the next available provider" with the $70 charge applied once unless you are on a TRT program. The homepage advertises the plans as "FSA, HSA Eligible".

We did not create an account or complete an intake, so what the checkout actually asks for — the length of the questionnaire, whether labs are ordered before or after the visit, how long approval takes — is not something this review can tell you. None of it is published.

TRT requires labs, and PeterMD sells a testing line — a biomarker panel and a biological-age product — alongside the prescriptions. What it does not publish is a monitoring schedule. None of the product pages we read states an interval for follow-up bloodwork, so the cadence is not something a prospective patient can check before signing up.

For sermorelin and NAD+ the picture is thinner still. Neither product page describes follow-up bloodwork as part of the subscription. Patients pay for the medication. What ongoing clinical review looks like after that is not spelled out.

Trustpilot is where a lot of DTC telehealth reviews get triaged, and PeterMD's profile there is worth flagging specifically. As of early September 2026, Trustpilot's page for getpetermd.com states: "This profile has been removed. The business you're trying to find goes against our guidelines and is no longer visible on Trustpilot."

That is the finding. Not the star rating, not the review count — Trustpilot pulled the page. Which makes the "4.9/5, Based on 20k+ Reviews" badge — on the homepage and repeated on the tirzepatide landing page — harder to place, because the site never says where those reviews live.

PeterMD sells tirzepatide from two of its own pages, and the pages disagree about what it costs and who may buy it.

The product page prices it at $299.00 a month and lists twenty-seven jurisdictions it cannot ship to — twenty-six states and the District of Columbia: AL, AR, CA, CT, DC, DE, GA, ID, IN, KY, LA, MA, MI, MN, MS, MO, NV, NM, NC, OH, PA, SC, TX, VT, VA, WA and WV.

The category page for the same drug offers it at "$149" to start, "Then $249 per month • billed quarterly • 60mg", and says only "Not available in these states: AL, ID".

Two against twenty-seven is not a discrepancy a reader can resolve by reading more carefully. Someone in Texas or California is either excluded or not, depending which page they land on, and the difference decides whether they can lawfully be sold the drug at all. The price gap is the smaller problem of the two.

A search of the FDA's warning-letter database for "PeterMD" returns no letter under that name. That result comes with a caveat that matters more than usual here: because no legal entity is published anywhere on the site, there is no way to know what corporate name a letter would be filed under.

The same gap runs through the contract. A patient agreeing to PeterMD's terms is agreeing to individual arbitration under Oklahoma law, with a class-action waiver, a jury-trial waiver and a two-year limitations period, against a counterparty identified only as "PeterMD". If something goes wrong, the first question a lawyer asks is who you contracted with, and the site does not answer it.

We are not confident recommending PeterMD to a specific reader profile, for the reasons this review has laid out: an efficacy claim on the tirzepatide page that the cited trials don't support, two of its own pages that contradict each other on price and legal availability of the same drug, no named prescriber or medical director, a removed Trustpilot profile, and a review score with no visible source.

A patient who is deeply experienced with hormone optimisation, who knows exactly what dose and formulation they want, and who is willing to carry the counterparty risk, might tolerate the tradeoffs. For most readers, the category has better-documented options.

PeterMD does three things better than the DTC telehealth median: it publishes TRT pricing in plain tiers, it publishes state exclusions on each product page, and it names its compounding pharmacies with street addresses. Those are real transparency signals and they should be credited.

Everything else pushes the other direction. A published weight-loss figure that the footnote beneath it contradicts. A patient count that its own homepage contradicts. A review score with nowhere to check it. Two prices and two state lists for one drug. And no prescriber, no medical director and no legal entity named anywhere on the site.

We wouldn't use PeterMD ourselves at the current state of its public disclosures.

From PeterMD’s public pages, read Sep 24, 2026.

Its terms carry a "Pharmacy Disclosure" section naming two pharmacies, and say prescriptions go to a pharmacy of the patient's choosing. No prescriber or medical group is named on the home page, the about page or the terms.

Read from: PeterMD terms, section 23.

How the other providers we cover answer the same question: which telehealth providers name their pharmacy.

Editorial note: This page is for informational purposes and doesn't constitute medical advice. Peptide and hormone therapy decisions should be made with a licensed healthcare provider familiar with your medical history.